Additions: Color green and underlined: text
addition example
Deletions: Color red and strikethrough: text
deletion example
ACIPHEX (rabeprazole Na) Tablets
[August 15, 2001: Eisai]
ADVERSE REACTIONS
Post-Marketing Adverse Events:
Post-Marketing Adverse Events: Additional adverse events reported from marketing experience with rabeprazole sodium are: sudden death, coma and hyperammonemia, jaundice, rhabdomyolysis, disorientation and delirium, anaphylaxis, angioedema, bullous and other drug eruptions of the skin, interstitial pneumonia, and TSH elevations. In most instances, the relationship to rabeprazole sodium was unclear. In addition, agranulocytosis, hemolytic anemia, leukopenia, pancytopenia, and thrombocytopenia have been reported.
Return to Quick Reference | MedWatch Home | MedWatch Safety Info | Online MedWatch Report | Contact Medwatch
ADENOSCAN (adenosine) Injection
[August 31, 2001: Fujisawa]
PRECAUTIONS/Drug Interactions:
First sentence, second paragraph:
"alkylxanthines" has been changed to "methylxanthines"
PRECAUTIONS/Carcinogenesis, Mutagenesis, Impairment of Fertility:
The second paragraph has been changed from:
Adenosine, however, like other nucleosides at millilmolar concentrations present for several doubling times of cells in culture, is known to produce a variety of chromosomal alterations. In rats and mice, adenosine administered intraperitoneally once a day for five days at 50, 100, and 150 mg/kg [10-30 (rats) and 5-15 (mice) times human dosage on a mg/M 2 basis] caused decreased spermatogenesis and increased numbers of abnormal sperm, a reflection of the ability of adenosine to produce chromosomal damage.
To the following:
Adenosine, however, like other nucleosides at millimolar concentrations present for several doubling times of cells in culture, is known to produce a variety of chromosomal alterations.
Fertility studies in animals have not been conducted with adenosine.
Geriatric Use:
Clinical studies of Adenoscan did not include sufficient numbers of subjects aged younger than 65 years to determine whether they respond differently. Other reported experience has not revealed clinically relevant differences of the response of elderly in comparison to younger patients. Greater sensitivity of some older individuals, however, cannot be ruled out.
Return to Quick Reference | MedWatch Home | MedWatch Safety Info | Online MedWatch Report | Contact Medwatch
AGGRENOX (aspirin/extended-release dipyridamole)
Capsules
[August 10, 2001:Boehringer Ingelheim]
CLINICAL PHARMACOLOGY:
Pharmacokinetics/Dipyridamole/Effect of Food:
No food effect study has been conducted with the AGGRENOX formulation.
To the following:
When AGGRENOX capsules were taken with a high fat meal, dipyridamole peak plasma levels (Cmax) and total absorption (AUC) were decreased at steady-state by 20-30% compared to fasting. Due to the similar degree of inhibition of adenosine uptake at these plasma concentrations, this food effect is not considered clinically relevant.
CLINICAL PHARMACOLOGY:
Pharmacokinetics/Aspirin:
Effect of Food: When AGGRENOX capsules were taken with a high fat meal, there was no difference for aspirin in AUC at steady-state, and the approximately 50% decrease in Cmax was not considered clinically relevant based on a similar degree of cyclo-oxygenase inhibition comparing the fed and fasted state.
DOSAGE AND ADMINISTRATION:
Addition of the following sentence as the last sentence of the first paragraph:
AGGRENOX capsules may be administered with or without food.
Return to Quick Reference | MedWatch Home | MedWatch Safety Info | Online MedWatch Report | Contact Medwatch
AREDIA (pamidronate disodium) Injection
[August 17, 2001, Novartis]
CLINICAL PHARMACOLOGY
Pharmacodynamics
Clinical Trials
In a fourth multicenter, randomized, double-blind trial, 103 patients with cancer and hypercalcemia (corrected serum calcium > 12.0 mg/dl) received 90 mg of Aredia as a 2-hour infusion. The mean baseline corrected serum calcium was 14.0 mg/dl. Patients were not required to receive IV hydration prior to drug administration, but all subjects did receive at least 500 ml of IV saline hydration concomitantly with the pamidronate infusion. By day 10 after drug infusion, 70% of patients had normal corrected serum calcium levels (< 10.8 mg/dl).
Unlike Aredia 60 mg, the drug has not been investigated in a controlled clinical trial employing a 90 mg dose infused over a 4 hour period.
ADVERSE REACTIONS
Clinical Studies
Hypercalcemia of Malignancy
Second paragraph revised -
Drug-related local soft-tissue symptoms (redness, swelling or induration and
pain on palpation) at the site of catheter insertion were most common (18%)
in patients treated with 90 mg of Aredia. When
all on-therapy events are considered, that rate rises to 41%.
Symptomatic treatment resulted in rapid resolution in all patients.
Fourth paragraph revised and a fifth paragraph added -
Five of 231 patients (2%) who received Aredia during the four U.S. controlled hypercalcemia clinical studies were reported to have had seizures, 2 of whom had preexisting seizure disorders. None of the seizures were considered to be drug-related by the investigators. However, a possible relationship between the drug and the occurrence of seizures cannot be ruled out. It should be noted that in the saline arm 1 patient (4%) had a seizure.
There are no controlled clinical trials comparing the efficacy and safety of 90 mg Aredia over 24 hours to 2 hours in patients with hypercalcemia of malignancy. However, a comparison of data from separate clinical trials suggests that the overall safety profile in patients who received 90 mg ArediaÒ over 24 hours is similar to those who received 90 mg Aredia over 2 hours.. The only notable differences observed were an increase in the proportion of patients in the ArediaÒ 24 hour group who experienced fluid overload and electrolyte/mineral abnormalities.
DOSAGE AND ADMINISTRATION
Hypercalcemia of Malignancy
Moderate Hypercalcemia
The recommended dose of Aredia in moderate hypercalcemia (corrected serum
calcium* of approximately 12-13.5 mg/dL) is 60 to 90 mg given
as a SINGLE DOSE, intravenous infusion over 2 to 24 hours Longer infusions (i.e.,
> 2 hours) may reduce the risk for renal toxicity, particulary in patients
with pre-existing renal insufficiency. The
60 mg dose is given as an initial, SINGLE DOSE, intravenous infusion over at
least 4 hours. The 90 mg dose must be given by an initial, SINGLE DOSE, intravenous
infusion over 24 hours. For select patients 90 mg can be infused over 2 to 24
hours.
Severe Hypercalcemia
The recommended dose of Aredia in severe hypercalcemia (corrected serum
calcium*>13.5 mg/dL) is 90 mg given as a SINGLE
DOSE, intravenous infusion over 2 to 24 hours. Longer infusions (i.e., >
2 hours) may reduce the risk for renal toxicity, particularly in patients with
pre-existing renal insufficiency. The
90 mg dose must be given by an initial, SINGLE DOSE, intravenous infusion over
24 hours. For select patients 90 mg can be infused over 2 to 24 hours.
*Albumin-corrected serum calcium (CCa,mg/dL) = serum calcium, mg/dL + 0.8 (4.0-serum albumin, g/dL).
Preparation of Solution
Hypercalcemia of Malignancy
The daily dose must be administered as an intravenous infusion over at least
-4- 2
to 24 hours for the 60-mg dose, and
2 to 24 hours for the and 90-mg
doses. The recommended dose should be diluted
in 1000 mL of sterile 0.45% or 0.9% Sodium Chloride, USP, or 5% Dextrose Injection,
USP. This infusion solution is stable for up to 24 hours at room temperature.
Return to Quick Reference | MedWatch Home | MedWatch Safety Info | Online MedWatch Report | Contact Medwatch
AZULFIDINE EN-TABS (sulfasalazine) Tablets
[August 16, 2001, Pharmacia & Upjohn]
PRECAUTIONS:
Drug Interactions:
Second and third paragraphs added -
When daily doses of sulfasalazine 2 g and weekly doses of methotrexate 7.5 mg were coadministered to 15 rheumatoid arthritis patients in a drug-drug interaction study, the pharmacokinetic disposition of the drugs was not altered.
Daily doses of sulfasalazine 2g (maximum 3g) and weekly doses of methotrexate 7.5mg (maximum 15 mg) were administered alone or in combination to 310 rheumatoid arthritis patents in two controlled 52-week clinical studies. The overall toxicity profile of the combination revealed an increased incidence of gastrointestinal adverse events, especially nausea, when compared to the incidence associated with either drug administered alone.
Return to Quick Reference | MedWatch Home | MedWatch Safety Info | Online MedWatch Report | Contact Medwatch
BIAXIN XL FILMTABS (clarithromycin) Tablets
[August 2, 2001: Abbott]
INDICATIONS AND USAGE:
Adults (BIAXIN Filmtab tablets and Granules for oral suspension):
Community-Acquired Pneumonia due to Haemophilus influenzae, Mycoplasma pneumoniae, Streptococcus pneumoniae, or Chlamydia pneumoniae (TWAR)
Children (BIAXIN Filmtabs and Granules for oral suspension):
Community-Acquired Pneumonia due to Mycoplasma pneumoniae, Streptococcus pneumoniae, or Chlamydia pneumoniae (TWAR)
Adults (BIAXIN XL Filmtab tablets):
Community-Acquired Pneumonia due to Haemophilus influenzae, Haemophilus parainfluenzae, Moraxella catarrhalis, Streptococcus pneumoniae, Chlamydia pneumoniae (TWAR), or Mycoplasma pneumoniae
ADVERSE REACTIONS:
First, third and fifth paragraphs -
The majority of side effects observed in clinical trials were of a mild and
transient nature. Fewer than 3% of adult patients without mycobacterial infections
and fewer than 2% of pediatric patients without mycobacterial infections discontinued
therapy because of drug-related side effects. Fewer than 3%
2% of adult patients taking BIAXIN XL tablets
discontinued therapy because of drug-related side effects.
The most frequently reported events in adults taking BIAXIN XL were diarrhea
(6%), abnormal taste (6%) (7%),
and nausea (3%). Most of these events were described as mild or moderate in
severity. Of the reported adverse events, less than 2%
1% were described as severe.
In community-acquired pneumonia studies conducted in adults comparing clarithromycin to erythromycin base or erythromycin stearate, there were fewer adverse events involving the digestive system in clarithromycin-treated patients compared to erythromycin-treated patients (13% vs 32%; p<0.01). Twenty percent of erythromycin-treated patients discontinued therapy due to adverse events compared to 4% of clarithromycin-treated patients.
DOSAGE AND ADMINISTRATION:
ADULT DOSAGE GUIDELINES
BIAXIN Tablets
|
BIAXIN XL Tablets
|
Infection |
Dosage
(q12h) |
Duration
(days) |
Dosage
(q24h) |
Duration
(days) |
Community-Acquired Pneumonia due to | ||||
H. influenzae |
250 mg
|
7
|
2 x 500 mg
|
7
|
H. parainfluenzae |
-
|
-
|
2 x 500 mg
|
7
|
M. catarrhalis |
-
|
-
|
2 x 500 mg
|
7 |
S. pneumoniae |
250 mg
|
7-14
|
2 x 500 mg
|
7
|
C. pneumoniae |
250 mg
|
7-14
|
2 x 500 mg
|
7
|
M. pneumoniae |
250 mg
|
7-14
|
2 x 500 mg
|
7
|
Return to Quick Reference | MedWatch Home | MedWatch Safety Info | Online MedWatch Report | Contact Medwatch
CEREBYX (fosphenytoin) Injection
[August 13, 2001: Parke-Davis]
Labeling provides for revision of carton/container labeling to reflect
concentration as a function of total container content rather than content per mL. This change was effected in response to several reports of overdose where health care providers mistakenly assumed that the amount of Cerebyx ® per mL was the final amount provided by the total vial. Contact the company for a copy of the new carton/container labeling.
OVERDOSAGE:
There is no experience with Cerebyx overdosage in humans.
Nausea, vomiting, lethargy, tachycardia, bradycardia, asystole, cardiac arrest, hypotension, syncope, hypocalcemia, metabolic acidosis, and death have been reported in cases of overdosage with fosphenytoin.
Return to Quick Reference | MedWatch Home | MedWatch Safety Info | Online MedWatch Report | Contact Medwatch
CEREZYME (imiglucerase) Injection
[August 13, 2001: Genzyme]
WARNINGS:
[Not in 2000 PDR]
Last paragraph added:
Anaphylactoid reaction has been reported in less than 1% of the patient population. Further treatment with imiglucerase should be conducted with caution. Most patients have successfully continued therapy after a reduction in rate of infusion and pretreatment with antihistamines and/or corticosteroids.
PRECAUTIONS:
General
[Not in 2000 PDR]
New first pargraph:
In less than 1% of the patient population, pulmonary hypertension has also been observed during treatment with Cerezyme. Pulmonary hypertension is a known complication of Gaucher disease, and has been observed both in patients receiving and not receiving Cerezyme. No causal relationship with Cerezyme has been established. Patients with respiratory symptoms should be evaluated for the presence of pulmonary hypertension.
ADVERSE REACTIONS:
[Not in 2000 PDR]
Revisions to first, second and third paragraphs:
Experience in patients treated with Cerezyme (imiglucerase for injection)
has revealed that approximately 8.5%
9.8% of patients experienced adverse events
which were judged to be related to Cerezyme administration
Symptom suggestive of hypersensitivity have been noted in approximately 4.0%
4.4% of patients. Onset of such symptoms
has occurred during or shortly after infusion; these symptoms include pruritus,
flushing, urticaria/angioedema, chest discomfort, respiratory symptoms, cyanosis
and hypotension. Anaphylactoid reaction has also been
reported. (see WARNINGS). Each of these events were found
to occur in < 1% of the total patient population. Pre-treatment with antihistamines
and/or corticosteroids and reduced rate of infusion has allowed continued use
of Cerezyme in most patients.
Additional adverse reactions that have been reported in approximately 4.5%
5.4% of patients treated with Cerezyme include:
nausea, abdominal pain, diarrhea, rash
DOSAGE AND ADMINISTRATION:
Second paragraph revised:
Cerezyme should be stored at 2-8° C. (36-46° F.). After reconstitution, Cerezyme should be inspected visually before use. Being a protein solution, slight flocculation (described as thin translucent fibers) occurs occasionally after dilution. The diluted solution may be filtered through an in-line low protein-binding 0.2 µm filter during administration. Any vials exhibiting opaque particles or discoloration should not be used. DO NOT USE Cerezyme
after the expiration date on vial.
Fourth paragraph, third sentence revised:
Cerezyme is administered by intravenous infusion over 1-2 hours or
at a rate between 0.5 1.0 unit per kg body weight per minute.
Aseptic techniques should be used
Return to Quick Reference | MedWatch Home | MedWatch Safety Info | Online MedWatch Report | Contact Medwatch
CLOZARIL (clozapine) Tablets
[August 29, 2001: Novartis]
INDICATIONS AND USAGE:
First paragraph - "antipsychotic"
replaced with "for schizophrenia" and "antipsychotic
drugs" replaced with "treatments for
schizophernia".
CONTRAINDICATIONS:
Clozaril (clozapine) is contraindicated in patients with severe renal disease, including acute renal failure. In addition, Clozaril is poorly dialyzable because it is highly protein bound. Therefore patients on dialysis should not take Clozaril (clozapine).
WARNINGS:
General:
First paragraph - "ANTIPSYCHOTIC"
replaced with "FOR SCHIZOPHRENIA".
PRECAUTIONS:
Anticholinergic Toxicity
Prostate
Clozaril (clozapine) has potent anticholinergic effects and care should be exercised in using this drug in the presence of prostatic enlargement.
Drug Interactions
Pharmacodynamic-related interactions -
Rare but serious reports of seizures, including onset of seizures in non-epileptic patients, and isolated cases of delirium where Clozaril (clozapine) was coadministered with valproic acid have been reported.
Clozaril (clozapine) may potentiate the hypotensive effects of antihypertensive drugs and the anticholinergic effects of atropine-like drugs. The administration of epinephrine should be avoided in the treatment of drug induced hypotension because of a possible reverse epinephrine effect. - moved from Pharmacokinetic-related interactions.
Pharmacokinetic-related interactions -
Clozapine is a substrate for many CYP 450 isoenzymes,
in particular 1A2, 2D6, and 3A4. The risk of metabolic interactions caused by
an effect on an individual isoform is therefore minimized. Nevertheless, caution
should be used in patients receiving concomitant treatment with other drugs
which are either inhibitors or inducers of these enzymes. Because
Clozaril (clozapine) is highly bound to serum protein, the administrationof
Clozaril (clozapine) to a patient taking another drug which is highly bound
to protein (e.g., warfarin, digitoxin) may cause an increase in plasma concentrations
of these drugs, potentially resulting in adverse effects. Conversely, adverse
effects may result from displacement of protein bound Clozaril (clozapine) by
other highly bound drugs.
Cimetidine and erythromycin may both increase
plasma levels of Clozaril (clozapine), potentially resulting in adverse effects.
Concomitant administration of drugs known
to induce cytochrome P450 enzymes may decrease the plasma levels of clozapine.
Phenytoin, nicotine, and rifampin
may decrease Clozaril (clozapine) plasma levels, resulting in a decrease in
effectiveness of a previously effective Clozaril (clozapine) dose.
Concomitant administration of drugs known to inhibit the activity of cytochrome P450 isoenzymes may increase the plasma levels of clozapine. Cimetidine, caffeine, and erythromycin may increase plasma levels of Clozaril (clozapine), potentially resulting in adverse effects. Moved from third paragraph - Although concomitant use of Clozaril (clozapine) and carbamazepine is not recommended, it should be noted that discontinuation of concomitant carbamazepine administration may result in an increase in Clozaril (clozapine) plasma levels.
ADVERSE REACTIONS:
Postmarketing Clinical Experience
Vision Disorders: narrow angle glaucoma
DOSAGE AND ADMINISTRATION
Initial Treatment
Second paragraph - "antipsychotic"
replaced with "for schizophrenia".
Therapeutic Dose Adjustment
Second paragraph - Clozaril (clozapine) can cause EEG changes, including the occurrence of spike and wave complexes. It lowers the seizure threshold in a dose- dependent manner and may induce myoclonic jerks or generalized seizures. These symptoms may be likely to occur with rapid dose increase in patients with pre-existing epilepsy. In this case, the dose should be reduced and, if necessary, anticonvulsant treatment initiated.
Maintenance Treatment
"antipsychotic" replaced with
"used to treat schizophrenia"
Discontinuation of Treatment
In the event of planned termination of Clozaril (clozapine) therapy, gradual reduction in dose is recommended over a 1-2 week period. However, should a patient's medical condition require abrupt discontinuation (e.g., leukopenia), the patient should be carefully observed for the recurrence of psychotic symptoms and symptoms related to cholinergic rebound such as headache, nausea, vomiting, and diarrhea.
Return to Quick Reference | MedWatch Home | MedWatch Safety Info | Online MedWatch Report | Contact Medwatch
COZAAR (losartan potassium) Tablets
&
HYZAAR (losartan potassium/hydrochlorothiazide) Tablets
[August 24, 2001: Merck]
ADVERSE REACTIONS:
Post-Marketing Experience
Hypersensitivity: Angioedema, including swelling of the larynx and glottis, causing airway obstruction and/or swelling of the face, lips, pharynx, and/or tongue has been reported rarely in patients treated with losartan; some of these patients previously
experienced angioedema with other drugs including ACE inhibitors. Vasculitis, including Henoch-Schoenlein purpura, has been reported with losartan. Anaphylactic reactions have been reported.
Return to Quick Reference | MedWatch Home | MedWatch Safety Info | Online MedWatch Report | Contact Medwatch
Cupric Chloride Injection
[August 29, 2001: Abbott]
CLINICAL PHARMACOLOGY:
Osteoporosis - Added to the list of copper deficiency symptoms.
Pediatric Use:
See DOSAGE AND ADMINISTRATION section. There are limited data in infants weighing less than 1500 grams.
DOSAGE AND ADMINISTRATION:
The statement following the sentence:
"For pediatric patients, the suggested additive ."
Infants weighing less than 1500 gm may have increased requirements because of their low body reserves and increased requirements for growth.
OVERDOSAGE:
Copper toxicity can also result in hemolysis and liver toxicity, including hepatic necrosis which may be fatal Added prior to the last sentence "D-penicillamine has been reported ."
Return to Quick Reference | MedWatch Home | MedWatch Safety Info | Online MedWatch Report | Contact Medwatch
Dextrose 5% & Sodium Chloride 0.225% w/ Potassium Chloride
0.075%, 0.224% & 0.3% Injection
&
Dextrose 5% & Sodium Chloride 0.3% w/ Potassium Chloride 0.075%,
0.15% & 0.224% Injection
[August 24, 2001: Abbott]
Geriatric Use
An evaluation of current literature revealed no clinical experience identifying differencesin response between elderly and younger patients. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy. Sodium and potassium ions are known to be substantially excreted by the kidney, and the risk of toxic reactions may be greater in patients with impaired renal function. Because elderly patients are more likely to have decreased function, care should be taken in dose selection, and it may be useful to monitor renal function.
Return to Quick Reference | MedWatch Home | MedWatch Safety Info | Online MedWatch Report | Contact Medwatch
DILAUDID (hydromorphone HCl) Oral Liquid
& Tablets
[August 22, 2001: Knoll]
PRECAUTIONS:
Special Risk Patients
A third paragraph is added as follows:
Reports of mild to severe seizures and myoclonus have been reported in severely compromised patients, administered high doses of parenteral hydromorphone, for cancer and severe pain. Opioid administration is associated with seizures and myoclonus in a variety of diseases where pain control is the primary focus.
Geriatric Use:
Clinical studies of Dilaudid did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy. (see INDIVIDUALIZATION
OF DOSAGES and PRECAUTIONS)."
SAFETY AND HANDLING INSTRUCTIONS:
First paragraph, second sentence:
..DILAUDID ORAL LIQUID should be treated by removal of any
contaminated clothing and rinsing the affected area with cool water.
HOW SUPPLIED:
STORAGE:
DILAUDID ORAL LIQUID and DILAUDID 8 mg TABLETS should be stored at 15 0 -25 0 C (590-77 0 F). Protect from light.
Changed to:
Store at 25 0 C (77 0 F); excursions permitted to 15 0 -30 0 C (59 0 -86 0 F). [See USP Controlled Room Temperature].
Return to Quick Reference | MedWatch Home | MedWatch Safety Info | Online MedWatch Report | Contact Medwatch
DOPRAM (doxapram HCl) Injection
[August 23 , 2001: Wyeth-Ayerst]
INDICATIONS AND USAGE
Postanesthesia.
To pharmacologically stimulate deep breathing in the
so-called " stir-up " regimen in the
postoperative patient. (A quantitative method of assessing
oxygenation, such as pulse oximetry, is recommended.) (Simultaneous
administration of oxygen is desirable.)
Chronic pulmonary disease associated with acute hypercapnia.
Doxapram is indicated as a temporary measure in hospitalized patients with
acute respiratory insufficiency superimposed on chronic obstructive pulmonary
disease. Its use should be for a short period of time (approximately
2 hours see DOSAGE AND ADMINISTRATION)
as an aid in the prevention of elevation of arterial CO2 tension during the
administration of oxygen. It should not be used in conjunction with mechanical
ventilation.
CONTRAINDICATIONS
Due to its benzyl alcohol content, Dopram Injectable is
contraindicated should not be used
in neonates newborns.
(See WARNINGS and PRECAUTIONS, Pediatric use.
WARNINGS
Doxapram should not be used in conjunction with mechanical ventilation.
This product contains benzyl alcohol as a preservative. Benzyl alcohol has been associated with a fatal "gasping syndrome" in neonates (see CONTRAINDICATIONS and PRECAUTIONS, Pediatric use.)
In postanesthetic use.
a. Doxapram is neither an antagonist to muscle relaxant drugs nor a specific
narcotic antagonist. More specific tests (e.g., peripheral
nerve stimulation, airway pressures, head-lift, pulse oximetry, and end-tidal
carbon dioxide) to assess adequacy of ventilation are recommended before administering
doxapram. Adequacy of airway and oxygenation
must be assured prior to doxapram administration.
e. In patients who have received general anesthesia utilizing a volatile agent known to sensitize the myocardium to catecholamines, administration of doxapram should be delayed until the volatile agent has been excreted in order to lessen the potential for arrhythmias, including ventricular tachycardia and ventricular fibrillation (see PRECAUTIONS, Drug interactions.)
PRECAUTIONS
General.
c. Monitoring of the blood pressure, pulse rate, and deep tendon reflexes is recommended to prevent overdosage.
g. Anticonvulsants such as intravenous short-acting barbiturates, along with oxygen and resuscitative equipment should be readily available to manage overdosage manifested by excessive central nervous system stimulation. Slow administration of the drug and careful observation of the patient during administration and for some time subsequently are advisable. These precautions are to assure that the protective reflexes have been restored and to prevent possible post-hyperventilation or hypoventilation.
In chronic obstruction pulmonary disease.
b. Arterial blood gases should be drawn prior to the initiation of doxapram infusion and oxygen administration, then at least every 1/2 hour during the infusion period to prevent development of CO2 retention and acidosis in patients with chronic obstructive pulmonary disease with acute hypercapnia. Doxapram administration does not diminish the need for careful monitoring of the patient or the need for supplemental oxygen in patients with acute respiratory failure. Doxapram should be stopped if the arterial blood gases deteriorate, and mechanical ventilation initiated.
DRUG INTERACTIONS:
Third paragraph:
In patients who have received general anesthesia utilizing
a volatile agent anesthetics
known to sensitize the myocardium to catecholamines, such
as halothane, cyclopropane and enflurane, administration
initiation of doxapram therapy
should be delayed until the volatile agent has been
excreted in order to lessen the potential for arrhythmias, including ventricular
tachycardia and ventricular fibrillation (see WARNINGS)
for at least 10 minutes following discontinuance of anesthesia, since an increase
in epinephrine release has been noted with doxapram.
Pediatric use.
Safety and effectiveness in pediatric patients below the age of 12 years have not been established. This product contains benzyl alcohol as a preservative. Benzyl alcohol has been associated with a fatal "gasping syndrome" in neonates (see CONTRAINDICATIONS and WARNINGS). The "gasping syndrome", characterized by central nervous system depression, metabolic acidosis, gasping respirations, and high levels of benzyl alcohol and its metabolites found in the blood and urine, has been associated with exposure to benzyl alcohol in neonates and low-birth-weight neonates. Additional symptoms may include gradual neurological deterioration, seizures, intracranial hemorrhage, hematologic abnormalities, skin breakdown, hepatic and renal
failure, hypotension, bradycardia, and cardiovascular collapse.
The use of the preservative benzyl alcohol in the newborn has been associated with metabolic, CNS, respiratory, circulatory, and renal dysfunction. Safety and effectiveness in children below the age of 12 years have not been established.
Premature neonates given doxapram doses of 2 to 2.5 mg/kg/h have developed irritability, jitteriness, hyperglycemia, glucosuria, abdominal distension, increased gastric residuals, vomiting, erratic limb movements, excessive crying, disturbed sleep, and, in premature neonates with risk factors such as perinatal asphyxia and intracerebral hemorrhage, seizures, and second- degree heart block caused by QT prolongation. In all instances, doxapram was administered following administration of xanthine derivatives such as aminophylline or theophylline
ADVERSE REACTIONS
The following Adverse reactions
reported coincident with the administration of Dopram
include: have been reported:
3. Cardiovascular.
Phlebitis, variations in heart rate, lowered T-waves, arrhythmias (including ventricular tachycardia and ventricular fibrillation), chest pain, tightness in chest. A mild to moderate increase in blood pressure is commonly noted and may be of concern in patients with severe cardiovascular diseases.
5. Genitourinary.
Stimulation of urinary bladder with spontaneous voiding; urinary retention.
Elevation of BUN and albuminuria. have
also been observed [text relocated from #6 below]
6. Hemic and Lymphatic.
Laboratory determinations.
A decrease in hemoglobin, hematocrit, or red blood cell count has been observed
in postoperative patients. In the presence of pre-existing leukopenia, a further
decrease in WBC has been observed following anesthesia and treatment with doxapram
hydrochloride. Elevation of BUN and albuminuria
have also been observed. As some of the patients cited above had received mukltiple
drugs concomitnatly, a cause and effect relationship could not be determined.
DOSAGE AND ADMINISTRATION
In postanesthetic use.
By infusion.
The solution is prepared by adding 250 mg of doxapram (12.5 mL) to 250 mL of dextrose 5% or 10% in water or normal saline solution.
METHOD TWO
By Intermittent I.V. Infusion
Chronic obstructive pulmonary disease associated with acute hypercapnia.
a. One vial of doxapram (400 mg) should be mixed with 180 mL of dextrose 5% or 10% or normal saline solution (concentration of 2.0 mg/mL).
Return to Quick Reference | MedWatch Home | MedWatch Safety Info | Online MedWatch Report | Contact Medwatch
EpiPen & EpiPen Jr. (epinephrine)
AutoInjectiors
[August 27, 2001:Meridian Medical Technologies]
New labeling provides for an additional packaging configuration for the EpiPen and EpiPen Jr. AutoInjectors. In addition, the labeling provides for revisions in the labeling and patient package insert as well as inclusion of a new trainer patient package insert. Contact the company for a copy of the new labeling material.
Return to Quick Reference | MedWatch Home | MedWatch Safety Info | Online MedWatch Report | Contact Medwatch
EPIVIR-HBV (lamivudine) Tablets &
Oral Solution.
[August 16, 2001: GlaxoSmithKline]
New labeling provides for the use of Epivir-HBV in the treatment of hepatitis B in pediatric patients ages 2-17 years. Contact the company for a copy of the new labeling/package insert.
Return to Quick Reference | MedWatch Home | MedWatch Safety Info | Online MedWatch Report | Contact Medwatch
Heparin Sodium in 0.9% NaCl
[August 21, 2001:Baxter Healthcare]
CLINICAL PHARMACOLOGY
Third paragraph revised to:
Patients over 60 years of age, following similar doses of heparin, may have higher plasma levels of heparin and longer activated partial thromboplastin times (APTTs) compared with patients under 60 years of age.
PRECAUTIONS
General
Increased Risk
c. Increased Risk in Older Patients, Especially Women:
A higher incidence of bleeding has been reported in patients, particularly women, over 60 years of age."
Pediatric Use:
Safety and effectiveness in pediatric patients have not been established.
Geriatric Use:
A higher incidence of bleeding has been reported in patients over 60 years
of age, especially women (see Precautions, General). Clinical studies indicate that lower doses of heparin may be indicated in these patients (see Precautions, General and Clinical Pharmacology).
Return to Quick Reference | MedWatch Home | MedWatch Safety Info | Online MedWatch Report | Contact Medwatch
LOPID (gemfibrozil) Tablets
[August 8, 2001: Pfizer]
Other safety related information regarding Lopid: http://www.fda.gov/medwatch/safety/2001/safety01.htm#bayco2
CONTRAINDICATIONS:
1. Combination therapy of LOPID with cerivastatin due to the increased risk of myopathy and rhabdomyolysis (see WARNINGS).
2. Hepatic or severe renal dysfunction, including primary biliary cirrhosis.
3. Preexisting gallbladder disease (see WARNINGS).
4. Hypersensitivity to gemfibrozil.
WARNINGS:
5. Concomitant therapy with Lopid and Mevacor
(lovastatin) has been associated with rhabdomyolysis, markedly elevated creatine
kinase (CK) levels and myoglobinuria, leading in a high proportion of cases
to acute renal failure. IN VIRTUALLY ALL PATIENTS WHO HAVE HAD AN UNSATISFACTORY
LIPID RESPONSE TO EITHER DRUG ALONE, ANY POTENTIAL LIPID BENEFIT OF COMBINED
THERAPY WITH LOVASTATIN AND GEMFIBROZIL DOES NOT OUTWEIGH THE RISKS OF SEVERE
MYOPATHY, RHABDOMYOLYSIS, AND ACUTE RENAL FAILURE (see Drug Interactions).
5. Concomitant therapy with LOPID and an HMG-CoA reductase inhibitor is associated with an increased risk of skeletal muscle toxicity manifested as rhabdomyolysis, markedly elevated creatine kinase (CPK) levels and myoglobinuria, leading in a high proportion of cases to acute renal failure and death. Because of an observed marked increased risk of myopathy and rhabdomyolysis, the specific combination of LOPID and cerivastatin is absolutely contraindicated (see CONTRAINDICATIONS). IN
PATIENTS WHO HAVE HAD AN UNSATISFACTORY LIPID RESPONSE TO
EITHER DRUG ALONE, THE BENEFIT OF COMBINED THERAPY WITH LOPID AND HMG-CoA REDUCTASE INHIBITORS OTHER THAN CERIVASTATIN DOES NOT OUTWEIGH THE RISKS OF SEVERE MYOPATHY, RHABDOMYOLYSIS, AND ACUTE RENAL FAILURE (refs. 7, 8, 9, 10) (see Drug Interactions). The use of fibrates alone, including LOPID may occasionally be associated with myositis. Patients receiving LOPID and complaining of muscle pain, tenderness, or weakness should have prompt medical evaluation for myositis, including serum creatine-kinease level determination. If myositis is suspected or diagnosed, LOPID therapy should be withdrawn.
PRECAUTIONS:
Drug Interactions
3. Drug Interactions(A) HMG-CoA reductase inhibitors:
Rhabdomyolysis has occurred with combined gemfibrozil
and lovastatin therapy. It may be seen as early as 3 weeks after initiation
of combined therapy or after several months. In most subjects who have had an
unsatisfactory lipid response to either drug alone, the possible benefit of
combined therapy with lovastatin (or other HMG CoA reductase inhibitors) and
gemfibrozil does not outweigh the risks of severe myopathy, rhabdomyolysis,
and acute renal failure. There is no assurance that periodic monitoring of creatine
kinase will prevent the occurrence of severe myopathy and kidney damage.
3. Drug Interactions(A) HMG-CoA reductase inhibitors: The risk of myopathy and rhabdomyolysis is increased with combined gemfibrozil and HMG-CoA reductase inhibitor therapy (see CONTRAINDICATIONS). Myopathy or rhabdomyolysis with or without acute renal failure have been reported as early as three weeks after initiation of combined therapy or after several months (refs. 7, 8, 9, 10). (See WARNINGS.) There is no assurance that periodic monitoring of creatine kinase will prevent the occurrence of severe myopathy and kidney damage.
OVERDOSAGE:
There have been reported cases of overdosage with LOPID. In one case, a 7-year-old child recovered after ingesting up to 9 grams of LOPID. Symptoms reported with overdosage were abdominal cramps, abnormal liver function tests, diarrhea, increased CPK, joint and muscle pain, nausea and vomiting. Symptomatic supportive measures should be taken, should an overdose occur.
REFERENCES:
7. Pierce LR, Wysowski DK, Gross TP. Myopathy and rhabdomyolysis associated with lovastatin/gemfibrozil combination therapy. JAMA 1990;264:71-75.
8. Bermingham RP, Whitsitt TB, Smart ML et al. Rhabdomyolysis in a patient receiving the combination of cerivastatin and gemfibrozil. Am J Health-Syst Pharm 2000;57:461-464.
9. Duell PB, Connor WE, Illingworth DR. Rhabdomyolysis after taking atorvastatin with gemfibrozil. Am J Cardiol 1998;81:368-369.
10. Tal A, Rajeshawari M, Isley W. Rhabdomyolysis associated with simvastatin/gemfibrozil therapy. South Med J 1997;90:546-547.
Return to Quick Reference | MedWatch Home | MedWatch Safety Info | Online MedWatch Report | Contact Medwatch
LOPROX (ciclopirox) Cream
[August 17, 2001: Aventis]
Labeling provides for elimination of the inactive ingredient Cocamide DEA from the formulation, substitution of Mineral Oil, USP, with new inactive ingredient Mineral Oil Light, NF.
Return to Quick Reference | MedWatch Home | MedWatch Safety Info | Online MedWatch Report | Contact Medwatch
MAXAIR (pirbuterol acetate) Inhaler
[August 14, 2001: 3M Pharmaceuticals]
DESCRIPTION: and PRECAUTIONS: Information for Patients: sections
As with all aerosol medications, it is recommended to prime (test) MAXAIR Inhaler before using for the first time and in cases where the inhaler has not been used for more than 2 weeks. Prime by releasing three "test sprays" into the air away from yourself and other people.
DOSAGE AND ADMINISTRATION: section and the PATIENTS
INSTRUCTIONS FOR USE:
It is recommended to "test spray" MAXAIR Inhaler into the air before using for the first time and in cases where the aerosol has not been used for a prolonged period of time.
As with all aerosol medications, it is recommended to prime (test) MAXAIR Inhaler before using for the first time and in cases where the inhaler has not been used for more than 2 weeks. Prime by releasing three "test sprays" into the air away from yourself and other people.
Return to Quick Reference | MedWatch Home | MedWatch Safety Info | Online MedWatch Report | Contact Medwatch
NORVIR (ritonavir) Capsules & Oral
Solution
[August 21, 2001: Abbott]
[Other labeling changes not appearing in 2001 PDR: http://www.fda.gov/medwatch/SAFETY/2001/mar01.htm#norvir]
CLINICAL PHARMACOLOGY:
Pharmacokinetics:
Hepatic Insufficiency:
Ritonavir pharmacokinetics have not been studied
in In six HIV-infected
adult subjects with mild hepatic insufficiency (see PRECAUTIONS).
dosed with NORVIR 400 mg BID, ritonavir exposures were similar to control subjects dosed with 500 mg BID. Adequate pharmacokinetic data are not available for patients with moderate hepatic impairment. Protein binding of ritonavir was not statistically significantly affected by mild or moderately impaired hepatic function (see PRECAUTIONS and DOSAGE AND ADMINISTRATION).
CONTRAINDICATIONS:
Second paragraph -
NORVIR should not be administered concurrently
Co-administration of NORVIR is contraindicated with the drugs listed in Table
3 (also see PRECAUTIONS Table 4: Drugs That
Should Not Be Co-administered with NORVIR) because competition
for primarily CYP3A by ritonavir could result in inhibition of the metabolism
of these drugs and create the potential for serious and/or life-threatening
reactions such as cardiac arrhythmias, prolonged or increased sedation, and
respiratory depression.
WARNINGS:
Drug Interactions:
Ritonavir is an inhibitor of cytochrome P450 3A (CYP3A) both in vitro and in vivo. Ritonavir also inhibits CYP2D6 in vitro, but to a lesser extent than CYP3A. Co-administration of ritonavir and drugs primarily metabolized by CYP3A or CYP2D6 may result in increased plasma concentrations of other drugs that could increase or prolong its therapeutic and adverse effects (see Pharmacokinetics: Drug-Drug Interactions, CONTRAINDICATIONS Table 3 Drugs
That Are Contraindicated with NORVIR, PRECAUTIONS Table 4 Drugs That Should Not Be Co-administered with NORVIR, Established Drug Interactions and Predicted Drug Interactions).
The magnitude of the interactions and therapeutic consequences between ritonavir and the drugs listed in Table 4 Predicted Drug Interactions: Use With Caution cannot be predicted with any certainty. When co-administering ritonavir with any agent listed in Table 4 Predicted Drug Interactions: Use With Caution, special attention is warranted. Refer to PRECAUTIONS: Established Drug Interactions and Predicted Drug Interactions for additional information.
PRECAUTIONS:
General
Ritonavir is principally metabolized by the liver. Therefore, caution should be exercised when administering this drug to patients with impaired hepatic function (see WARNINGS, CLINICAL PHARMACOLOGY: Hepatic Insufficiency and DOSAGE AND ADMINISTRATION: Dose Adjustment in Hepatic Insufficiency).
Fat Redistribution: "protease inhibitors"
was deleted and replaced with "antiretroviral therapy."
Information For Patients: "protease inhibitors"
was deleted and replaced with "antiretroviral therapy"
in the sixth paragraph to be consistent with prior subsection on Fat Redistribution.
Drug Interactions:
Table 4: Drug Interactions With NORVIR has been renamed and reformatted. The renamed table now reads Table 4: Drugs That Should Not be Co-administered with NORVIR.
Table 4
Drugs That Should Not Be Co-administered with NORVIR
Drug Interactions With NORVIR
CONTRAINDICATED DRUGS (Same as Table 3)
|
|
Drug Class: Drug Name |
Drugs Within Class That Are CONTRAINDICATED With NORVIR Clinical Comment |
Antiarrhythmics: amiodarone, bepridil, flecainide, propafenone, quinidine |
CONTRAINDICATED due to potential for serious and/or life threatening reactions such as cardiac arrhythmias. |
Antihistamines: astemizole, terfenadine |
CONTRAINDICATED due to potential for serious and/or life-threatening reactions such as cardiac arrhythmias. |
Ergot Derivatives: dihydroergotamine, ergonovine, ergotamine, methylergonovine |
CONTRAINDICATED due to potential for serious and/or life-threatening reactions such as acute ergot toxicity characterized by peripheral vasospasm and ischemia of the extremities and other tissues. |
GI Motility Agent: cisapride |
CONTRAINDICATED due to potential for serious and/or life-threatening reactions such as cardiac arrhythmias. |
Herbal Products: St. Johns wort (hypericum perforatum) |
May lead to loss of virologic response and possible resistance to NORVIR or to the class of protease inhibitors. |
HMG-CoA Reductase Inhibitors: lovastatin, simvastatin |
Potential for serious reactions such as risk of myopathy including rhabdomyolysis. |
Neuroleptic: pimozide |
CONTRAINDICATED due to the potential for serious and/or life-threatening reactions such as cardiac arrhythmias. |
Sedative/hypnotics: midazolam, triazolam |
CONTRAINDICATED due to the potential for serious and/or life- threatening reactions such as prolonged or increased sedation or respiratory depression. |
Established Drug Interactions: Alteration in Dose or
Regimen Recommended Based on Drug Interaction Studies
(see CLINICAL PHARMACOLOGY, Table 2 for Magnitude of Interaction)
Concomitant Drug Class: Drug Name
|
Effect on Concentration of Ritonavir or Concomitant Drug |
Clinical Comment |
HIV-Antiviral Agents |
||
HIV Protease Inhibitor: Indinavir |
When co-administered with reduced doses of indinavir and ritonavir indinavir (« AUC ¯ Cmax Cmin ) |
Alterations in concentrations are noted when reduced doses of indinavir are co-administered with Norvir. Appropriate doses for this combination, with respect to efficacy and safety, have not been established |
HIV Protease Inhibitor: saquinavir |
When co- Administered with reduced doses of saquinavir and ritonavir saquinavir ( AUC Cmax Cmin ) |
|
Other Agents |
||
Antimycobacterial: rifampin |
¯ ritonavir |
May lead to loss of virologic response. Alternate antimycobacterial agents such as rifabutin should be considered (see Antimycobacterial: rifabutin, for dose reduction recommendations) |
Table 4: Predicted Drug Interactions: Use With Caution, Dose Decrease of
Coadministered Drug May Be Needed (see WARNINGS) had two revisions. Under the Examples of Drugs subheading, rapamycin was added but lovastatin and simvastatin were moved to Table 4: Drugs That Should Not Be-Co-administered with NORVIR. Additionally, a footnote 2 was added to this table and reads, " 2Use lowest possible dose of atorvastatin or cerivastatin with careful monitoring or consider HMG-CoA reducatase inhibitor such as pravastatin or fluvastatin."
Carcinogenesis and Mutagenesis:
Long term carcinogenicity studies of ritonavir in animal systems have not been completed. However, ritonavir was not mutagenic or clastogenic in a battery of in vitro and in vivo assays including bacterial reverse mutation (Ames) using S. typhimurium and E. coli, mouse lymphoma, mouse micronucleus, and chromosome aberrations in human lymphocytes.
Carcinogenicity studies in mice and rats have been carried out on ritonavir. In male mice, at levels of 50, 100 or 200 mg/kg/day, there was a dose dependent increase in the incidence of both adenomas and combined adenomas and carcinomas in the liver. Based on AUC measurements, the exposure at the high dose was approximately 0.3-fold for males that of the exposure in humans with the recommended therapeutic dose (600 mg BID). There were no carcinogenic effects seen in females at the dosages tested. The exposure at the high dose was approximately 0.6-fold for the females that of the exposure in humans. In rats dosed at levels of 7, 15 or 30 mg/kg/day there were no carcinogenic effects. In this study, the exposure at the high dose was approximately 6% that of the exposure in humans with the recommended therapeutic dose. Based on the exposures achieved in the animal studies, the significance of the observed effects is not known. However, ritonavir was found to be negative for mutagenic or clastogenic activity in a battery of in vitro and in vivo assays including the Ames bacterial reverse mutation assay using S. typhimurium and E. coli, the mouse lymphoma assay, the mouse micronucleus test and chromosomal aberration assays in human lymphocytes.
Antiretroviral Pregnancy Registry: To monitor maternal-fetal outcomes of pregnant women exposed to NORVIR, an Antiretroviral Pregnancy Registry has been established. Physicians are encouraged to register patients by calling 1-800-258-4263.
Nursing Mothers: It is not known whether
this drug is excreted in human milk. The
Centers for Disease Control and Prevention recommend that HIV-infected mothers
not breast-feed their infants to avoid risking postnatal transmission of HIV.
It is not known whether ritonavir is
secreted in human milk. Because of both the potential for HIV transmission and
the potential for serious adverse reactions in nursing infants, mothers should
be instructed not to breast-feed if they are receiving NORVIR.
Because many drugs are excreted in human milk,
caution should be exercised
when ritonavir is administered to a nursing woman. However, the U.S. Public
Heath Service Centers for Disease Control and Prevention advises HIV infected
women not to breast feed to avoid postnatal transmission of HIV to a child who
may not be infected.
Geriatric Use:
Clinical studies of NORVIR did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal or cardiac function, and of concomitant disease or other drug therapy.
OVERDOSAGE:
Management of Overdosage:
The following paragraph was added to the beginning of this subsection:
NORVIR oral solution contains 43% alcohol by volume. Accidental ingestion of the product by a young child could result in significant alcohol-related toxicity and could approach the potential lethal dose of alcohol.
DOSAGE AND ADMINISTRATION:
Pediatric Patients:
Dose Adjustment in Hepatic Insufficiency
The ritonavir dose does not need to be adjusted in patients with mild hepatic impairment. At this time, there are insufficient data in patients with moderate to severe hepatic impairment; therefore, NORVIR should be used with caution in this patient population (see Special Populations: Hepatic Insufficiency and PRECAUTIONS).
Patient Package Insert
What is NORVIR and how does it work?
NORVIR is in a class of drugs
medicines called the HIV protease (PRO-tee-ase)
inhibitors. NORVIR is used in combination with other anti-HIV drugs
medicines to treat people with human immunodeficiency virus (HIV)
infection. NORVIR is for adults and for children age
2 years and older.
How should I take NORVIR?
NORVIR is available only with a doctor's prescription.
You should stay under a doctors care when taking
NORVIR. Do not change your treatment or stop treatment without first talking
with your doctor.
When your NORVIR supply starts to run low, get more from your doctor or pharmacy. This is very important because the amount of virus in your blood may increase if the medicine is stopped for even a short time. The virus may develop resistance to NORVIR and become harder to treat.
What happens if I take too much NORVIR?
If you think that you took more than the prescribed dose of this medicine, contact your local poison control center or emergency room immediately.
As with all prescription medicines, NORVIR should be kept out of the reach of young children. NORVIR liquid contains a large amount of alcohol. If a toddler or young child accidentally drinks more than the recommended dose of NORVIR, it could make him/her sick from too much alcohol. Contact your local poison control center or emergency room immediately if this happens.
Who should not take NORVIR?
Do not take NORVIR if you are taking certain medicines. These could cause serious side effects that could cause death. Before you take NORVIR, you must tell your doctor about all the medicines you are taking or are planning to take. These include other prescription and non-prescription and herbal supplements.
For more information about medicines you should not take with NORVIR, please read the section "MEDICINES YOU SHOULD NOT TAKE WITH NORVIR."
Do not take NORVIR if you are taking certain medications. Taking certain drugs with NORVIR could create the potential for serious side effects that could be life threatening. You must tell your doctor about all the drugs you are taking or are planning to take before you take NORVIR. More information about drugs that interact with NORVIR can be found in the section "Can I take NORVIR with other medications?"
MEDICINES YOU SHOULD NOT TAKE WITH NORVIR.
Ergotamine, ergonovine, methylergonovine, and dihydroergotamine such as Cafergot , Migranal , D.H.E 45 , and others
Do not take NORVIR with the cholesterol-lowering medicines
Mevacor (lovastatin) or Zocor (simvastatin) because of possible serious reactions.
There is also an increased risk of drug interactions between NORVIR and Lipitor
(atorvastatin) and Baycol (cerivastatin); talk to your doctor
before you take any of these cholesterol-reducing medicines withNORVIR.
Drugs Medicines
that require dosage adjustments:
The following drugs
medicines require dose reduction if taken with NORVIR:
Mycobutin ® (rifabutin) Your doctor will lower your dose of Mycobutin
The following drug reduces blood levels of NORVIR:
If you are taking Mycobutin (rifabutin), your doctor
will lower the dose of Mycobutin.
Other Special Considerations:
NORVIR oral solution contains alcohol. Talk with your doctor if you are taking or planning to take metronidazole or disulfiram. Severe nausea and vomiting can occur.
If you are taking both didanosine (Videx) and NORVIR: Didanosine and Norvir should be separated by at least 2.5 hours.
Rifamate , may reduce blood levels of NORVIR. Be sure to tell your doctor if you are taking rifampin.
What are the possible
side effects might I have while taking
of NORVIR?
This list of side effects is not complete. Your
doctor or pharmacist can discuss with you a more complete list of possible side
effects with NORVIR. Talk to your doctor promptly about any side effects you
have. If you have questions about side
effects, ask your, doctor, nurse, or pharmacist. You should report any new or
continuing symptoms to your doctor right away. Your doctor may be able to help
you manage these side effects.
Abnormal liver function Blood
tests have been reported in
patients taking NORVIR may show possible liver problems.
People with liver disease such as Hepatitis B and Hepatitis C who take NORVIR
may have worsening liver disease. Liver problems including rare cases
of death have occurred in patients taking NORVIR. It
is unclear if NORVIR caused these liver People
with pre-existing liver disease may have worsening of liver disease.
Some problems
because some patients had other illnesses or were taking other medicines.
drugs. It is uncertain if NORVIR caused these liver problems.
Some patients taking NORVIR can develop serious problems with their pancreas
(pancreatitis) which may cause death. Tell your doctor if you have nausea, vomiting, or abdominal pain. These may be signs of pancreatitis.
Some patients have large increases in triglycerides and cholesterol. The long-term chance of getting complications such as heart attacks or stroke due to increases in triglycerides and cholesterol caused by protease inhibitors is not known at this time.
Changes in body fat have been seen in some patients taking protease
inhibitors. anti-HIV medicines.
These changes may include increased amount
of fat in the upper back and neck ("buffalo hump"), breast and
abdomen (stomach area). Loss of fat from
the face, legs, and arms may also happen. The cause and long-term health effects
of these conditions are not known at this time.
Inflammation of their pancreas (pancreatitis), including some deaths, have occurred in some patients taking NORVIR.
Some patients have had large increases in triglycerides
and cholesterol. The long-term risks for complications such as heart attacks
or stroke due to increases in triglycerides and cholesterol are not known at
this time. with hemophilia have increased
bleeding with protease inhibitors.
Increased bleeding has been reported in some patients with hemophilia.
There have been other side effects noted in patients receiving NORVIR; however,
these side effects may have been due to other drugs
medicines that
patients were taking or to the illness itself. Some
of these side effects can be serious. If
you have questions about side effects, ask your doctor, nurse, or pharmacist.
You should report any new or persistent symptoms to your doctor immediately.
What Should should
I tell my doctor before taking NORVIR?
If you are pregnant or planning to become
pregnant: The effects of NORVIR on pregnant women or their unborn
babies are not known. If you are pregnant or plan
to become pregnant, you should
tell your doctor before taking NORVIR.
If you are breast-feeding: Do not breast-feed if you are taking NORVIR. You should not breast-feed if you have HIV. If you are a woman who has or will have a baby, talk with your doctor about the best way to feed your baby. You should be aware that if your baby does not already have HIV, there is a chance that HIV can be transmitted through breast-feeding.
....Other medical problems: Certain medical problems
may affect the use of NORVIR. If
you have diabetes:
Some people taking protease inhibitors have
developed develop
new or more serious diabetes or high blood sugar. Be
sure to tell your doctor if you have diabetes or an increase in thirst and/or
frequent urination.
If you have hemophilia:
Some people with hemophilia have had increased bleeding. It is not known
whether the protease inhibitors caused these problems. Be sure to tell your
doctor if you have hemophilia types A and B, diabetes
mellitus, or an increase in thirst and/or frequent urination.
Whom should I call if I have questions about NORVIR?
If you would like more information about NORVIR, ask your doctor or pharmacist. If you have any questions or concerns about taking NORVIR, talk with your doctor.
If you suspect that you took more than the prescribed dose of this medicine, contact your local poison control center or emergency room immediately.
General advice about prescription medicines:
Talk to your doctor or other health care provider if you have any questions about this medicine or your condition. Medicines are sometimes prescribed for purposes other than those listed in a Patient Information Leaflet. If you have any concerns about this medicine, ask you doctor. Your doctor or pharmacist can give you information about this medicine that was written for health care professionals. Do not use this medicine for a condition for which it was not prescribed. Do not share this medicine with other people.
Return to Quick Reference | MedWatch Home | MedWatch Safety Info | Online MedWatch Report | Contact Medwatch
ParaGard T380A (interuterine
copper contraceptive)
[August 24, 2001: R.W. Johnson Pharmaceutical Research Institute]
The ParaGard T380A should only be inserted, managed, and removed by clinicians that have demonstrated clinical competence for these procedures received under supervision.
INSTRUCTIONS FOR USE:
CLINICIANS SHOULD HAVE DEMONSTRATED CLINICAL COMPENTENCE IN PARAGARD T380A INSERTIONS, MANAGEMENT, AND REMOVAL RECEIVED UNDER SUPERVISION. PREVIOUS EDUCATION RE: SURGICAL PROCEDURES WILL REQUIRE VARYING LEVELS OF EXPERIENCE.
PATIENT PACKAGE INSERT:
How the ParaGard T380A Is Inserted and Removed
The ParaGard T380A should be inserted, managed, and removed by clinicians that have demonstrated clinical compentence for these procedures received under supervision.
Return to Quick Reference | MedWatch Home | MedWatch Safety Info | Online MedWatch Report | Contact Medwatch
PRINIVIL (lisinopril) &
PRINZIDE (lisinopril/hydrochlorothiazide) Tablets
[August 7, 2001: Merck]
CLINICAL PHARMACOLOGY:
Pharmacodynamics
The following paragraph has been added:
In a clinical pharmacology study, indomethacin or sulindac was administered to hypertensive patients receiving enalapril maleate. In this study there was no evidence of a blunting of the antihypertensive action of enalapril maleate. (See PRECAUTIONS, Drug Interactions.)
PRECAUTIONS:
Drug Interactions
Non-Steroidal Anti-inflammatory Agents:
In a clinical pharmacology study, indomethacin or sulindac was administered to hypertensive patients receiving enalapril maleate. In this study there was no evidence of a blunting of the antihypertensive action of enalapril maleate. However, reports suggest that NSAIDs may diminish the antihypertensive effect of ACE-inhibitors. This interaction should be given consideration in patients taking NSAIDs concomitantly with ACE-inhibitors.
Lisinopril
in a study in 36 patients with mild to moderate hypertension where the antihypertensive effects of lisinopril alone were compared to lisinopril given concomitantly with indomethacin, the use of
indomethacin was associated with a reduced effect, although the difference between the two
regimens was not significant
In a study in 36 patients with mild to moderate hypertension where the antihypertensive effects of lisinopril (40 mg q.d.) alone were compared to lisinopril (40 mg q.d.) given concomitantly with indomethacin (50 mg b.i.d.), the use of indomethacin was associated with a reduced antihypertensive effect of lisinopril, although the difference between the two regimens was not significant. Reports suggest that NSAIDs may diminish the antihypertensive effect of ACE inhibitors. This interaction should be given consideration in patients taking NSAIDs concomitantly with ACE-inhibitors.
DOSAGE AND ADMINISTRATION:
The following statement has been added to the end of the fourth paragraph:
Dosage higher than lisinopril 80 mg and hydrochlorothiazide 50 mg should not be used.
Return to Quick Reference | MedWatch Home | MedWatch Safety Info | Online MedWatch Report | Contact Medwatch
QUINIDEX EXTENTABS (quinidine
sulfate) Tablets
[August 18, 2001: Wyeth-Ayerst]
PRECAUTIONS:
Drug and Diet Interactions
Altered pharmacokinetics of quinidine:
Grapefruit juice inhibits P450 3A4-mediated metabolism of quinidine to
3-hydroxyquinidine. Although the clinical significance of this interaction is unknown, grapefruit juice should be avoided.
The rate and extent of quinidine absorption may be affected by changes in dietary salt intake; a decrease in dietary salt intake may lead to an increase in plasma quinidine concentrations
Geriatric Use:
Safety and efficacy of quinidine in elderly patients have not been systematically studied.
Clinical studies of quinidine generally were not adequate to determine if significant safety or efficacy differences exist between elderly patients (65 years or older) and younger patients.
Quinidine clearance is apparently independent of age (see CLINICAL PHARMACOLOGY-Pharmacokinetics). However, renal or hepatic dysfunction causes the elimination of quinidine to be slowed (see WARNINGS-Pharmacokinetic Considerations), and since these conditions are more common in the elderly, appropriate dosing reductions should be considered in these individuals.
OVERDOSAGE:
The following paragraph was added after the first paragraph:
A case of tablet ingestion by a 16-month-old infant has been reported in which a concretion or bezoar was formed in the stomach, resulting in nondeclining toxic levels of quinidine. The mass was only dimly visible on plain radiographs, but a gastric aspirate revealed quinidine levels approximately 50 times higher than those in plasma. In cases of massive overdose with prolonged high plasma levels, diagnostic/therapeutic endoscopy may be appropriate.
Return to Quick Reference | MedWatch Home | MedWatch Safety Info | Online MedWatch Report | Contact Medwatch
SERAX (oxazepam) Tablets
[August 8, 2001: Faulding]
PRECAUTIONS:
New subsection -
Geriatric Use:
Clinical studies of Serax were not adequate to determine whether subjects aged 65 and over respond differently than younger subjects. Age (<80 years old) does not appear to have a clinically significant effect on oxazepam kinetics (see CLINICAL PHARMACOLOGY).
Clinical circumstances, some of which may be more common in the elderly, such as hepatic or renal impairment, should be considered. Greater sensitivity of some older individuals to the effects of Serax (e.g., sedation, hypotension, paradoxical excitation) cannot be ruled out. (see PRECAUTIONS, General; see ADVERSE REACTIONS). In general, dose selection for Serax for elderly patients should be cautious, usually starting at the lower end of the dosing range (see DOSAGE AND ADMINISTRATION).
Return to Quick Reference | MedWatch Home | MedWatch Safety Info | Online MedWatch Report | Contact Medwatch
SINGULAIR (montelukast Na) Tablets
[August 2, 2001: Merck]
ADVERSE REACTIONS:
myalgia including muscle cramps, and very rarely seizure; and very rarely pancreatitis; increased bleeding tendency, bruising; and edema
Patient Product Information
What are the possible side effects of Singulair?
muscle aches, muscle cramps, seizure, pancreatitis, increased bleeding tendency, bruising and edema
Return to Quick Reference | MedWatch Home | MedWatch Safety Info | Online MedWatch Report | Contact Medwatch
Sodium Lactate Injection
[August 15, 2001: Abbott]
PRECAUTIONS:
Carcinogenesis, mutagenesis, impairment of fertility:
Studies with Sodium Lactate Injection have not been performed to evaluate carcinogenic potential, mutagenic potential or effects on fertility.
Nursing Mothers:
It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when Sodium Lactate Injection is administered to a nursing mother.
Return to Quick Reference | MedWatch Home | MedWatch Safety Info | Online MedWatch Report | Contact Medwatch
SUFENTA (sufentanil citrate) Injection
[August 28, 2001: Akorn]
CLINICAL PHARMACOLOGY:
Pharmacokinetics, Intravenous use subsection, a 2 nd sentence is added as follows:
The elimination half-life of SUFENTA is shorter (e.g. 97 ± 42 minutes) in infants and children, and longer in neonates (e.g. 434±160 minutes) compared to that of adolescents and adults.
PRECAUTIONS:
Pediatric Use:
The safety and efficacy of intravenous SUFENTA in children under two years of age undergoing cardiovascular surgery has been documented in a limited number of cases
Replaced by the following:
The safety and efficacy of intravenous SUFENTA in pediatric patients as young as 1 day old undergoing cardiovascular surgery have been documented in a limited number of cases. The clearance of SUFENTA in healthy neonates is approximately on-half that in adults and children. The clearance rate of SURENTA can be further reduced by up to a third in neonates with cardiovascular disease, resulting in an increase in the elimination
half-life of the drug.
ADVERSE REACTIONS:
Probably Causally related: Incidence Less than 1%-Derived from Clinical Trials:
At the end of the subsection, the word Incidence added before 0.3% to 1%
A new subsection that reads: Body as a whole: Anaphylaxis is added.
Cardiovascular: cardiac arrest is added.
DOSAGE AND ADMINISTRATION:
A last sentence added as follows:
Because the clearance of SUFENTA is reduced in neonates, especially those with cardiovascular disease, the dose of SUFENTA should be reduced accordingly (see PRECAUTIONS).
Return to Quick Reference | MedWatch Home | MedWatch Safety Info | Online MedWatch Report | Contact Medwatch
TEQUIN (gatifloxacin) Tablets
[August 20, 2001: Bristol Myers-Squibb]
CLINICAL PHARMACOLOGY
Glucose Homeostasis
The following paragraph was added and now appears first in this subsection:
As with other quinolones, clinical experience has shown that disturbances of blood glucose, including symptomatic hyper- and hypoglycemia, have been reported in patients treated concomitantly with TEQUIN and oral hypoglycemic agents with or without insulin. Therefore, careful monitoring of blood glucose is recommended when TEQUIN is administered to diabetic patients receiving treatment with oral hypoglycemic agents with or without insulin. (See PRECAUTIONS: General, Information for Patients, and Drug Interactions.)
PRECAUTIONS
General
The last paragraph was revised as follows:
As with other quinolones, disturbances of blood glucose, including symptomatic
hyper- and hypoglycemia, have been reported with TEQUIN,
usually in diabetic patients receiving concomitant treatment with oral hypoglycemic
agents (e.g., glyburide) or
with or without insulin. In these patients,
the careful monitoring of blood glucose
is recommended. If a hypoglycemic reaction occurs in
a patient being treated with TEQUIN, appropriate therapy should be initiated
immediately and TEQUIN should be discontinued. (See CLINICAL PHARMACOLOGY,
PRECAUTIONS: Drug Interactions, and ADVERSE REACTIONS.)
Information for Patients
The twelfth bullet was revised as follows:
·that if they are diabetic and are being treated with insulin or an oral hypoglycemic agent and a hypoglycemic reaction occurs, they should discontinue gatifloxacin and consult a physician (see PRECAUTIONS: General)."
·that if they are diabetic, disturbances of blood glucose, including symptomatic hyper- and hypoglycemia, have been reported in patients treated concomitantly with TEQUIN (as with other quinolones) and oral hypoglycemic agents with or without insulin. If a hypoglycemic reaction occurs, they should initiate appropriate therapy immediately, discontinue TEQUIN, and contact a physician (see PRECAUTIONS: General and Drug Interactions).
Drug Interactions
Antidiabetic agents has been added and appears second in this subsection as follows:
Antidiabetic agents: No significant pharmacokinetic interactions have been observed when glyburide was administered concomitantly with TEQUIN. However, disturbances of blood glucose, including symptomatic hyper- and hypoglycemia, have been reported in patients treated concomitantly with TEQUIN (as with other quinolones) and oral hypoglycemic agents with or without insulin. Therefore, careful monitoring of blood glucose is recommended when TEQUIN is administered to diabetic patients receiving treatment with oral hypoglycemic agents with or without insulin. (See CLINICAL PHARMACOLOGY and PRECAUTIONS: General and
Information for Patients.)
ADVERSE REACTIONS:
The fifth and sixth paragraphs were revised to include additional adverse events as follows:
Body as a Whole: allergic reaction, asthenia, back pain, chest pain, chills, face edema, fever, halitosis
Cardiovascular System: hypertension, palpitation
Digestive System: abdominal pain, anorexia, constipation, dyspepsia, flatulence, gastritis, glossitis, mouth ulcer, oral moniliasis, stomatitis, vomiting
Hemic/Lymphatic System: ecchymosis
Metabolic/Nutritional System: hyperglycemia, peripheral edema, thirst
Musculoskeletal System: arthralgia, leg cramp
Nervous System: abnormal dream, agitation, anxiety, confusion, hallucination, insomnia, nervousness, paresthesia, somnolence, tremor, vasodilatation, vertigo
Respiratory System: dyspnea, pharyngitis
Skin/Appendages: dry skin, pruritus, rash, sweating
Special Senses: abnormal vision, eye pain, taste perversion, tinnitus
Urogenital System: dysuria, hematuria
Additional drug-related adverse events considered clinically relevant that
occurred in <0.1% (rare adverse events) of patients receiving gatifloxacin
in single- and multiple-dose clinical trials are as follows: abnormal thinking,
agitation, alcohol intolerance,
anorexia, anxiety, arthalgia,
arthritis, asthenia, asthma (bronchospasm),
ataxia, bone pain, bradycardia, breast pain, cheilitis, colitis, confusion,
convulsion, cyanosis, depersonalization, depression, diabetes mellitus, dry
skin, dysphagia, ear pain, ecchymosis,
edema, epistaxis, euphoria, eye pain, face edema,
flatulence,
gastritis, gastrointestinal hemorrhage,
gingivitis, halitosis, hallucination,
hematemesis, hostility, hyperesthesia, hyperglycemia, hypertension, hypertonia,
hyperventilation, hypoglycemia, leg cramp, lymphadenopathy, maculopapular rash,
metrorrhagia, migraine, mouth edema, myalgia, myasthenia, neck pain, nervousness,
panic attack, paranoia, parosmia, pruritus,
pseudomembranous colitis, psychosis, ptosis, rectal hemorrhage, somnolence,
stress, substernal chest pain, tachycardia, taste loss, thirst,
tongue edema, vesiculobullous rash.
Patient Information About Tequin
What about other medications I am taking?
The following bullet was added and now appears third as follows:
· If you have diabetes, it is important to let your healthcare provider know if you are on oral hypoglycemic agents with or without insulin."
What are the possible side effects of TEQUIN?
A paragraph was added to the end of this section as follows:
If you have diabetes, you should know that disturbances of blood sugar, including symptoms of hyperglycemia (high blood sugar) and hypoglycemia (low blood sugar), have been reported in patients treated concomitantly with TEQUIN (as with other quinolone antibiotics) and oral antidiabetic drugs with or without insulin. If you develop symptoms of low blood sugar while on TEQUIN, you should take immediate measures to increase your blood sugar, stop taking TEQUIN, and contact your healthcare professional at once.
Return to Quick Reference | MedWatch Home | MedWatch Safety Info | Online MedWatch Report | Contact Medwatch
TOPAMAX (topiramate) Tablets & Sprinkle
Capsule
[August 28, 2001: R.W. Johnson]
Other safety related information: http://www.fda.gov/medwatch/safety/2001/safety01.htm#topama
Labeling provides for the use of Topamax (topiramate) Tablets,
Topamax (topiramate) Sprinkle Capsule as adjunctive therapy in patients 2 years and older with seizures associated with Lennox-Gastaut syndrome. Contact the company for a copy of the new labeling.
WARNINGS:
Acute myopia and secondary angle closure glaucoma
A syndrome consisting of acute myopia associated with secondary angle closure glaucoma has been reported in patients receiving TOPAMAX. Symptoms include acute onset of decreased visual acuity and/or ocular pain. Ophthalmologic findings can include myopia, anterior chamber shallowing, ocular hyperemia (redness) and increased intraocular pressure. Mydriasis may or may not be present. This syndrome may be associated with supraciliary effusion resulting in anterior displacement of the lens and iris, with secondary angle closure glaucoma. Symptoms typically occur within 1 month of initiating TOPAMAX therapy. In contrast to primary
narrow angle glaucoma, which is rare under 40 years of age, secondary angle closure glaucoma associated with topiramate has been reported in pediatric patients as well as adults. The primary treatment to reverse symptoms is discontinuation of TOPAMAX as rapidly as possible, according to the judgment of the treating physician. Other measures, in conjunction with discontinuation of TOPAMAX, may be helpful.
Elevated intraocular pressure of any etiology, if left untreated, can lead to serious sequelae including permanent vision loss.
PRECAUTIONS:
Information for Patients
Patients taking TOPAMAX® should be told to seek immediate medical attention if they experience blurred vision or periorbital pain.
Return to Quick Reference | MedWatch Home | MedWatch Safety Info | Online MedWatch Report | Contact Medwatch
ULTANE (sevoflurane) Liquid for
Inhalation
[August 8, 2001: Abbott]
Other information not appearing in the 2001 PDR: http://www.fda.gov/medwatch/SAFETY/2001/mar01.htm#ultane
PRECAUTIONS:
Hepatic Function
Third paragraph added:
Very rare cases of mild, moderate, and severe post-operative hepatic dysfunction or hepatitis with or without jaundice have been reported from postmarketing experiences. Clinical judgement should be exercised when sevoflurane is used in patients with underlying hepatic conditions or under treatment with drugs known to cause hepatic dysfunction (see ADVERSE REACTIONS).
ADVERSE REACTIONS:
Adverse Events During Post-Marketing Experience:
Last sentence of first paragraph removed:
One death has been reported in association with sevoflurane administration and seizures.
Third paragraph added:
Very rare cases of mild, moderate and severe post-operative hepatic dysfunction or hepatitis with or without jaundice have been reported. Histological evidence was not provided for any of the reported hepatitis cases. In most of these cases, patients had underlying hepatic conditions or were under treatment with drugs known to cause hepatic dysfunction. Most of the reported events were transient and resolved spontaneously (see PRECAUTIONS).
Return to Quick Reference | MedWatch Home | MedWatch Safety Info | Online MedWatch Report | Contact Medwatch
VALTREX (valacyclovir HCl) Caplets
[August 30, 2001: GlaxoSmithKline]
Labeling provides for a shorter treatment course of three days in the treatment of recurrent episodes of genital herpes. Contact the company for a copy of the new labeling/package insert.
Return to Quick Reference | MedWatch Home | MedWatch Safety Info | Online MedWatch Report | Contact Medwatch
VISUDYNE (verteporfin) Injection
[August 22, 2001: QLT]
Labeling provides for the use of Visudyne (verteporfin for injection) therapy for the treatment of patients with predominantly classic subfoveal choroidal neovascularization due to macular degeneration, presumed ocular histoplasmosis or pathologic myopia. Contact the company for a copy of the new labeling/package insert.
Return to Quick Reference | MedWatch Home | MedWatch Safety Info | Online MedWatch Report | Contact Medwatch
XALATAN(latanoprost) Ophthalmic
Solution
[August 7, 2001: Pharmacia & Upjohn]
WARNINGS:
Fourth paragraph -
XALATAN may gradually change eyelashes and vellus hair; these changes include increased length, thickness, pigmentation, and number of lashes or hairs, and misdirected growth of eyelashes.
PRECAUTIONS:
Information for Patients (see Warnings):
Second paragraph -
ADVERSE REACTIONS:
Clinical Practice: The following events have been identified during postmarketing use of XALATAN in clinical practice. Because they are reported voluntarily from a population of unknown size, estimates of frequency cannot be made. The events, which have been chosen for inclusion due to either their seriousness, frequency of reporting, possible causal connection to
XALATAN, or a combination of these factors, include: asthma and exacerbation
of asthma; corneal edema and erosions; dyspnea; eyelash and
vellus hair changes (increased length, thickness, pigmentation, and
number of lashes); eyelid skin
darkening; herpes keratitis; intraocular inflammation (iritis/uveitis); keratitis;
macular edema, including cystoid macular edema; misdirected
eyelashes sometimes resulting in eye irritation; and toxic epidermal
necrolysis.
Return to Quick Reference | MedWatch Home | MedWatch Safety Info | Online MedWatch Report | Contact Medwatch
ZAROXOLYN (metolazone) Tablets &
MYKROX (metolazone) Tablets
[August 10, 2001: Celltech Pharmaceuticals]
(Zaroxolyn)
(Mykrox)
WARNINGS: Rapid Onset Hyponatremia and/or Hypokalemia:
Hypokalemia:
Second sentence:
"Serum potassium should be determined at regular and appropriate intervals, and dose reduction ."
(Zaroxolyn)
ADVERSE REACTIONS: Dermatologic/Hypersensitivity:
Toxic epidermal necrolysis (TEN), Stevens-Johnson Syndrome, necrotizing angiitis (cutaneous vasculitis), purpura, dermatitis (photosensitivity), urticaria, and skin rashes.
Thrombocytopenia was deleted from the paragraph describing adverse reactions reported with similar antihypertensive-diuretics and added to Hematologic:
Hematologic:
Aplastic/hypoplastic anemia, agranulocytosis, leukopenia, thrombocytopenia.
Dry mouth was deleted from the paragraph describing adverse reactions reported with similar antihypertensive-diuretics and added to Other:
Other:
Transient blurred vision, chills, dry mouth.
(Mykrox)
ADVERSE REACTIONS: Dermatologic/Hypersensitivity:
Toxic epidermal necrolysis (TEN), Stevens-Johnson Syndrome, necrotizing angiitis (cutaneous vasculitis), purpura, dermatitis, photosensitivity, urticaria.
Thrombocytopenia was deleted from the paragraph describing rare adverse experiences reported in association with similar antihypertensive-diuretics and was added to:
Other Adverse Experiences:
Hematologic:
Hematologic: Aplastic (hypoplastic) anemia, agranulocytosis, leukopenia, thrombocytopenia.
Return to Quick Reference | MedWatch Home | MedWatch Safety Info | Online MedWatch Report | Contact Medwatch
ZOLOFT (sertraline HCl) Tablets &
Oral Concentrate
[August 6, 2001: Pfizer]
Other labeling changes not found in 2001 PDR: http://www.fda.gov/medwatch/SAFETY/2001/feb01.htm#zoloft , http://www.fda.gov/medwatch/safety/2000/nov00.htm#zoloft
Labeling provides for the use of Zoloft (sertraline hydrochloride) for the long-term treatment of posttraumatic stress disorder. Contact the company for a copy of the new labeling/package insert.
Return to Quick Reference | MedWatch Home | MedWatch Safety Info | Online MedWatch Report | Contact Medwatch
HTML by JLW